Biotech and Money London 2016 Testimonials




‘We know a lot of people and numbers of clients attending Biotech and Money London last year who gave us really good feedback and that’s why we decided to sponsor for the first time this year. The closed door sessions for the CEOs forum in particular is a very good idea. People got to network and have powerful and productive conversations with their peers which I don’t think others conferences provide for.’
Paul Claydon, Partner and Head, Corporate Practice, Europe, Covington & Burling LLP

‘The CEO Forum gave me the feeling that it’s a slightly different forum where CEOs actually did have some outcome from the discussions. It’s a particularly interesting forum to discuss changes in the UK biotech and pharma sectors.’
Peter George, CEO, Clinigen

‘It is extremely important to build relationships with entrepreneurs, academics and investors. Biotech and Money brings those people together. This is an excellent opportunity to build relationships with new people as well as catch up with old friends and colleagues from the sector.’
Sinclair Dunlop, Managing Partner, Epidarex Capital

‘Money in the sector is really important. It’s one of the things that’s moving and changing dynamically. If you look at who is here at Biotech and Money London and what has been covered it was just hitting all the right nails on head.’
Andy Richards, Chairman and Non-Executive Director, Serial Biotechnology Entrepreneur and Business Angel

‘Biotech and Money London is a time well spent!’
Gavin Clarke, Director of Licensing, CN Bio Innovations

‘What I really liked about Biotech and Money London is the opportunity to meet a lot of people from different aspects of the business and connect.’
Claire Brown, Investment Manager, Alderley Park Ventures


Watch the 2016 event highlights and exclusive interviews with the key industry executives.

‘Biotech and Money London is a mix of top rank investors with interesting investment opportunities.’
Damian Marron, EIR, Loxbridge

‘The content of the discussions makes Biotech and Money’s CEO forum an extremely worthwhile meeting, particularly given the very high calibre of people that attend … well done, I am a converted sceptic.’
John Beadle, CEO, PsiOxus

‘Biotech and Money’s HealthEx CEO forum is a truly unique and valuable gathering of some of the finest minds and leaders in healthcare. It’s calibre of attendee and opportunity to have genuine and honest peer discussion about the vital challenges we face is what sets it apart.’
Peter George, CEO, Clinigen

‘The CEO forum is a great opportunity to channel the expertise and know how of a powerful group of seasoned execs with a diverse experience for the benefit of the sector.’
Richard Goodfellow, CEO, Scancell

‘Biotech and Money produces high quality content and events that offer outstanding opportunities for investors, bioscience companies and stakeholders to connect and learn from each other. We are delighted to be a sponsor and partner.’
Nigel Pitchford, Chief Investment Officer, Imperial Innovations

‘The investor/partnering showcase presentations given by the next generation of British Life Sciences entrepreneurs and leading British Life Science companies in the ‘UK Ones to Watch’ session was a very efficient way to get a broad sweep of sector activity.’
David Ford, Founder, Arrowfield Capital

‘Biotech and Money London can certainly be defined as a very good networking event with interesting panel topics!’
Eva-Lotta Allan, CBO, Immunocore

‘Biotech and Money London offers a very current outlook on biotech and key industry opinions.’
Henrik Hagemann, Co-Founder, Customem

‘Biotech and Money London is undoubtedly an excellent place for networking opportunities.’
Melya Hughes Crameri, Partner, Ventac Partners

‘One of the distinctive features of Biotech and Money is that it presents an up to date insight into the thinking of the investment community.’
John Normanton, CEO, EstryX Pharma

‘Biotech and Money London gives the opportunity for a purchase funnel for drug development and perception management of UK relative world position.’
Hans Karten, Chief Executive Officer / Chief Technology Officer, Genalice B.V.

‘Biotech and Money London is a good opportunity to catch up with peers across the sector, meet some new people and find out about some promising up-and-coming companies.’
Mick Cooper, Analyst, Trinity Delta

‘Biotech and Money is a useful gathering of the UK biotech community.’
Roughan Sheedy, Finance and Commercial Director, Imanova

‘Biotech and Money London is a great networking experience. I’ve had meetings with a lot of promising contacts!’
Pascal Hughes, CEO, Levrett

‘The panel and group discussions at Biotech and Money London are really interesting and therefore the event ensures meaningful conversations.’
Sally Waterman, Senior VP Corporate Development, Abzena

‘What I like about Biotech and Money London is that we all get the chance to present our companies during the 1-2-1 partnering sessions, allowing us to make valuable contacts.’
Sarah Holland, Head of Europe, External Science and Partnering Strategy, Sanofi

‘The very high quality of investors and corporates are definitely here at Biotech and Money London.’
Siro Perez, Venture Partner, Hadean Ventures

‘The surroundings of Biotech and Money London is conducive to high quality networking opportunities.’
Adam Stolen, Head of Technology Transfer, Isis Innovation

‘Biotech and Money London brings together great speakers and hence a nice and interesting mix of attendees.’
Alan Robson, Relationship Director, Healthcare, Barclays Corporate

‘If you’re looking for strategies for business development and alliances from major firms all in one place, Biotech and Money London is definitely the place to be.’
Alan Scarse, SETsquared Business Incubation Centre Manager, University of Southampton

‘The 1-2-1 partnering, the very relevant presentations and meaningful discussions make Biotech and Money London an excellent event to attend.’
Bevan McWilliams, Business Development Manager, Royal Veterinary College

‘Biotech and Money London allows everyone to meet a broad range of high quality investors.’
Carlos Pittol, Director, Antikor Biopharma Ltd



Download the Post Event Report to:

  • see conference summary 
  • review agenda and speaker line-up 
  • view delegate list 
  • read attendee and partner testimonials 
  • meet event supporters and partners